Daisuke Tanaka

Daisuke Tanaka

Auto-generated profile, based on publicly available information

Daisuke Tanaka

Neuroscience Research Institute, AIST, Tsukuba, Ibaraki 305-8566, Japan

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2007 in Neuropharmacology
Verified
Journal Article
Closed access
DTDaisuke Tanaka
Daisuke Tanaka
KFKiyotaka Furusawa
Kiyotaka Furusawa
KKKimihiko Kameyama
Kimihiko Kameyama
HOHarumasa Okamoto
Harumasa Okamoto
MDMotomichi Doi
Motomichi Doi

13 June 2018 in Drug Safety
Verified
Journal Article
Open access
PDF file
RERike van Eekeren
Rike van Eekeren
LRLeàn Rolfes
Leàn Rolfes
Andries KosterAndries Koster
Andries Koster
LMLara Magro
Lara Magro
GPGurumurthy Parthasarathi
Gurumurthy Parthasarathi
LHLinda Härmark
Linda Härmark
Adverse drug reactions (ADRs) can cause serious health problems, as shown in studies about drug-related hospitalizations. To build knowledge of and raise awareness about ADRs among healthcare professionals, more education in the field of ADRs and pharmacovigilance (PV) is needed. No standard exists for teaching PV at universities for medical, pharmacy, dentistry and nursing students, so a core curriculum needs to be developed to teach important aspects of PV to students. In September 2016, a stakeholders’ meeting was initiated on behalf of the World Health Organization (WHO) and organized by the Netherlands Pharmacovigilance Centre Lareb. This meeting addressed and agreed on the PV competencies students need to develop and what key aspects of the subject should be taught. Five key aspects were identified: understanding the importance of PV in the context of pharmacotherapy, and preventing, recognizing, managing and reporting ADRs. Since time and resources for PV education are limited, elements of the WHO PV core curriculum for university teaching were designed to be integrated into existing courses but can be used as a stand-alone programme. The basis of and outline for the WHO PV core curriculum for university teaching are addressed in this paper. It is expected that PV competencies for students are vital for their contribution to safe use of medicines in the future. In addition, this article aims to stimulate discussion on this subject and promote collaboration between universities, national PV centres and other stakeholders to integrate key aspects of PV in their educational programmes.

21 October 2008 in Genes to Cells
Verified
Journal Article
Closed access
PDF file
DTDaisuke Tanaka
Daisuke Tanaka
KKKimihiko Kameyama
Kimihiko Kameyama
HOHarumasa Okamoto
Harumasa Okamoto
MDMotomichi Doi
Motomichi Doi

1 April 2000 in Neuroscience
Verified
Journal Article
Closed access
YIY. Ikegaya
Y. Ikegaya
YIY. Itsukaichi-Nishida
Y. Itsukaichi-Nishida
MIM. Ishihara
M. Ishihara
DTD. Tanaka
D. Tanaka
NMN. Matsuki
N. Matsuki

4 August 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
YKYoichi Kohno
Yoichi Kohno
AIAkihiro Ishiguro
Akihiro Ishiguro
TYTakashi Yasukawa
Takashi Yasukawa
NYNaoyuki Yasuda
Naoyuki Yasuda
DTDaisuke Tanaka
Daisuke Tanaka
YFYasuhiro Fujiwara
Yasuhiro Fujiwara
Review time for a new drug in Japan has shortened dramatically since the establishment of the Pharmaceuticals and Medical Devices Agency (PMDA). Nonetheless, Japan faces a new challenge so‐called “Drug Loss”, which means that new drugs approved overseas have not yet been developed in Japan or that development is delayed. In this manuscript, we describe how PMDA facilitates Japan’s drug development to continuously provide innovative drugs to patients.

1 January 2015 in Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku
Verified
Journal Article
Closed access
DTDaisuke Tanaka
Daisuke Tanaka